Lates News

Shares of Lilly rose more than 2% in pre-market trading as the company announced the results of the second obesity trial for Orforglipron. The drug resulted in a 9.6% weight loss for obese and diabetic patients. The company plans to apply for approval of the weight loss drug in 2025.